University of Rochester scientists have developed a novel method for noninvasive brain activation using bioluminescent optogenetics (BL-OG). This innovative approach combines optogenetics, which uses light to control brain cells, with bioluminescence.
The technique, detailed in a recent NeuroImage study, could improve treatments for neurological conditions like Parkinson's disease by eliminating the need for invasive brain implants. “BL-OG is an ideal method for noninvasively teasing apart neural circuits in the brain,” explains Dr. Manuel Gomez-Ramirez, the study's senior author.
BL-OG works by introducing light-sensitive proteins into specific brain regions of mice. Researchers then inject luciferin, a harmless organic compound, into the animal's bloodstream. The interaction between luciferin and bioluminescent proteins produces light, activating the optogenetic components and modulating targeted brain cells.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The team also reported that BL-OG effects occur rapidly and can be fine-tuned by adjusting luciferin dosage.
Dr. Gomez-Ramirez highlights the method's advantages: "We can create brain activation without a cable. There is less risk for infection and other complications because it is noninvasive." The researchers are now focused on refining BL-OG for potential laboratory and clinical applications.
An additional benefit of this technique is the ability to track neuromodulation effects through bioluminescent activity, providing valuable insights into brain function.